On November 26, 2024, Vivos Therapeutics held its annual stockholders meeting. Approximately 2.7 million shares were represented, constituting a quorum. Stockholders elected R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, and Dr. Matthew Thompson as directors for a one-year term.The meeting also approved the 2024 Omnibus Equity Incentive Plan, allowing contingent awards to certain officers, employees, and consultants. The voting results showed 957,268 shares in favor, 313,560 against, and 17,747 abstaining.Additionally, the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 2,496,723 shares in favor. These decisions align with the company's strategic goals.

On November 26, 2024, Vivos Therapeutics held its annual stockholders meeting. Approximately 2.7 million shares were represented, constituting a quorum. Stockholders elected R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, and Dr. Matthew Thompson as directors for a one-year term.The meeting also approved the 2024 Omnibus Equity Incentive Plan, allowing contingent awards to certain officers, employees, and consultants. The voting results showed 957,268 shares in favor, 313,560 against, and 17,747 abstaining.Additionally, the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 2,496,723 shares in favor. These decisions align with the company's strategic goals.